http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 18:15:10 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Biogen+completes+acquisition+of+RayThera+in+immunology+push/26885877.html <p>Biogen Inc. (Nasdaq: BIIB) announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology, according to a press release issued Aug. 6, 2026.</p> <p>The acquisition adds multiple assets to Biogen's immunology portfolio, with the lead program having entered Phase 1 clinical development in July 2026. Financial terms of the deal were not disclosed.</p> <p>Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen, commented on the deal: "With the lead program now in Phase 1, this acquisition highlights strong execution on our open innovation model in http://www.streetinsider.com/Mergers+and+Acquisitions/Biogen+completes+acquisition+of+RayThera+in+immunology+push/26885877.html Thu, 06 Aug 2026 18:15:10 -0400 BIIB http://www.streetinsider.com/Press+Releases/Biogen+Completes+Acquisition+of+RayThera+Inc./26885876.html <p><strong>Lead program now in Phase 1 development</strong></p><p>CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=XOu9keYNHL339hexlfwjjYn-uJJYaoOfPT_sPUJKZINxE2Uml6kuN5iQl54QxuXGi4lhtxHmfNuCKQiibFbMhA==" rel="nofollow" target="_blank">Biogen</a> Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.</p> <p>The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026.</p> <p>“We are excited about the potential of these immunology assets as we continue to strengthen http://www.streetinsider.com/Press+Releases/Biogen+Completes+Acquisition+of+RayThera+Inc./26885876.html Thu, 06 Aug 2026 18:15:00 -0400 BIIB http://www.streetinsider.com/Globe+Newswire/Biogen+Completes+Acquisition+of+RayThera+Inc./26885876.html <p><strong>Lead program now in Phase 1 development</strong></p><p>CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=XOu9keYNHL339hexlfwjjYn-uJJYaoOfPT_sPUJKZINxE2Uml6kuN5iQl54QxuXGi4lhtxHmfNuCKQiibFbMhA==" rel="nofollow" target="_blank">Biogen</a> Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.</p> <p>The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026.</p> <p>“We are excited about the potential of these immunology assets as we continue to strengthen http://www.streetinsider.com/Globe+Newswire/Biogen+Completes+Acquisition+of+RayThera+Inc./26885876.html Thu, 06 Aug 2026 18:15:00 -0400 BIIB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881063.html si-local-file:///var/storage/secattach/20260806/26881063.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881063.html Thu, 06 Aug 2026 10:18:00 -0400 BIIB O.00070139 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881063.html si-local-file:///var/storage/secattach/20260806/26881063.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881063.html Thu, 06 Aug 2026 10:18:00 -0400 BIIB O.00070139 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOGEN+INC.+++++++++++++++For%3A+Aug+03++Filed+by%3A+Minor+Lloyd/26873711.html si-local-file:///var/storage/secattach/20260805/26873711.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOGEN+INC.+++++++++++++++For%3A+Aug+03++Filed+by%3A+Minor+Lloyd/26873711.html Wed, 05 Aug 2026 16:03:00 -0400 BIIB O.00070139 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOGEN+INC.+++++++++++++++For%3A+Aug+03++Filed+by%3A+Minor+Lloyd/26873711.html si-local-file:///var/storage/secattach/20260805/26873711.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOGEN+INC.+++++++++++++++For%3A+Aug+03++Filed+by%3A+Minor+Lloyd/26873711.html Wed, 05 Aug 2026 16:03:00 -0400 BIIB O.00070139 http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html <p> BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. </p><p> A live webcast of the presentation, along with an archived replay, will be available in the Investors &amp; News http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870541.html Wed, 05 Aug 2026 08:00:00 -0400 BIIB O.00070139 O.41203217 STOK http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+Minor+Lloyd/26863994.html si-local-file:///var/storage/secattach/20260804/26863994.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+Minor+Lloyd/26863994.html Tue, 04 Aug 2026 11:23:00 -0400 BIIB O.00070139 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+Minor+Lloyd/26863994.html si-local-file:///var/storage/secattach/20260804/26863994.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOGEN+INC.++++++++++++++++++++++++++++Filed+by%3A+Minor+Lloyd/26863994.html Tue, 04 Aug 2026 11:23:00 -0400 BIIB O.00070139 http://www.streetinsider.com/Analyst+PT+Change/Biogen+%28BIIB%29+PT+Raised+to+%24241+at+Mizuho/26861016.html Mizuho analyst Salim Syed raised the price target on Biogen (NASDAQ: BIIB) to $241.00 (from $221.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Biogen+%28BIIB%29+PT+Raised+to+%24241+at+Mizuho/26861016.html Tue, 04 Aug 2026 06:39:28 -0400 BIIB http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html <p class="bwalignc"> <i>– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data</i> <i>readout anticipated in Q3 2027 –</i> </p><p class="bwalignc"> <i>– Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 –</i> </p><p class="bwalignc"> <i>– Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 –</i> </p><p class="bwalignc"> <i>– $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html Mon, 03 Aug 2026 16:01:00 -0400 A.06822034 BIIB O.00070139 O.20026344 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html <p class="bwalignc"> <i>– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data</i> <i>readout anticipated in Q3 2027 –</i> </p><p class="bwalignc"> <i>– Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 –</i> </p><p class="bwalignc"> <i>– Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 –</i> </p><p class="bwalignc"> <i>– $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html Mon, 03 Aug 2026 16:01:00 -0400 A.06822034 BIIB O.00070139 O.20026344 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html <p class="bwalignc"> <i>– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data</i> <i>readout anticipated in Q3 2027 –</i> </p><p class="bwalignc"> <i>– Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 –</i> </p><p class="bwalignc"> <i>– Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 –</i> </p><p class="bwalignc"> <i>– $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html Mon, 03 Aug 2026 16:01:00 -0400 A.06822034 BIIB O.00070139 O.20026344 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html <p class="bwalignc"> <i>– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data</i> <i>readout anticipated in Q3 2027 –</i> </p><p class="bwalignc"> <i>– Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 –</i> </p><p class="bwalignc"> <i>– Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 –</i> </p><p class="bwalignc"> <i>– $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html Mon, 03 Aug 2026 16:01:00 -0400 A.06822034 BIIB O.00070139 O.20026344 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html <p class="bwalignc"> <i>– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data</i> <i>readout anticipated in Q3 2027 –</i> </p><p class="bwalignc"> <i>– Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 –</i> </p><p class="bwalignc"> <i>– Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 –</i> </p><p class="bwalignc"> <i>– $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html Mon, 03 Aug 2026 16:01:00 -0400 A.06822034 BIIB O.00070139 O.20026344 O.41203217 STOK http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html <p class="bwalignc"> <i>– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data</i> <i>readout anticipated in Q3 2027 –</i> </p><p class="bwalignc"> <i>– Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 –</i> </p><p class="bwalignc"> <i>– Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 –</i> </p><p class="bwalignc"> <i>– $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through http://www.streetinsider.com/Press+Releases/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html Mon, 03 Aug 2026 16:01:00 -0400 A.06822034 BIIB O.00070139 O.20026344 O.41203217 STOK http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html <p class="bwalignc"> <i>– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data</i> <i>readout anticipated in Q3 2027 –</i> </p><p class="bwalignc"> <i>– Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 –</i> </p><p class="bwalignc"> <i>– Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 –</i> </p><p class="bwalignc"> <i>– $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through http://www.streetinsider.com/Business+Wire/Stoke+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26857524.html Mon, 03 Aug 2026 16:01:00 -0400 A.06822034 BIIB O.00070139 O.20026344 O.41203217 STOK